558 posters,  10 sessions,  5 topics,  1511 authors,  513 institutions
ePostersLive® by SciGen® Technologies S.A. All rights reserved.

IS-1
Management and Care Following Treatment With Venetoclax and Rituximab for Patients With Relapsed Chronic Lymphocytic Leukemia

Rate

Average: 4.1 (25 votes)

Management and Care Following Treatment With Venetoclax and Rituximab for Patients With Relapsed Chronic Lymphocytic Leukemia

 

INTRODUCTION

▪ Venetoclax is a highly selective, potent, orally bioavailable inhibitor of the antiapoptotic protein B-cell lymphoma 2 (BCL-2)1

▪ Venetoclax is approved as monotherapy in the United States, the European Union, and other countries for certain patients with relapsed/refractory chronic lymphocytic leukemia (CLL)2,3

▪ Venetoclax monotherapy resulted in a complete remission (CR) rate of 16 – 20% in patients with relapsed/refractory CLL, including those with high-risk chromosome 17p deletion.4,5 The 24-month progression-free survival (PFS) rate was 49%5

▪ Preclinical studies in B-cell malignancies have demonstrated synergistic activity of venetoclax in combination with the anti-CD20 antibody rituximab1

▪ In a phase 1b study of venetoclax combined with rituximab in patients with relapsed/refractory CLL (NCT01682616), the CR rate increased to 51%, with 59% of patients achieving minimal residual disease (MRD)-negativity.6,7 The 24-month PFS rate was 82%, with an ongoing response rate of 89%8

▪ Thus, durable responses with venetoclax as monotherapy or combination therapy suggest the possibility of maintaining response even after stopping venetoclax

 

Enter Poster ID (e.gGoNextPreviousCurrent